



## Leech Therapy (Jalaukavacharana): An Ancient Ayurvedic Practice and Its Modern Scientific Perspectives

Sarita Meena<sup>1\*</sup>, Vijay Shanker Yadav<sup>1</sup>, Bhola Nath Maurya<sup>1</sup>

### Abstract

**Background:** Leech therapy, known as Jalaukavacharana in Ayurveda, is one of the oldest para-surgical procedures documented in classical Ayurvedic texts, particularly the Sushruta Samhita. This form of Raktamokshana (bloodletting) employs the medicinal leech *Hirudomedicinalis* and related species to treat a wide spectrum of disorders linked to vitiated blood (Raktadushti) and Pitta-Rakta imbalances. **Objective:** This review aims to consolidate classical Ayurvedic knowledge of leech therapy with contemporary biomedical evidence, highlighting the pharmacological properties of leech saliva, mechanisms of therapeutic action, clinical indications, contraindications, and procedural protocols. **Methods:** A systematic search of classical Ayurvedic texts (Sushruta Samhita, Ashtanga Hridayam, Ashtanga Sangraha, Charaka Samhita) and modern databases including PubMed, Google Scholar, Scopus, and AYUSH research portals was conducted. Articles published between 1985 and 2025 were included. **Results:** The saliva of medicinal leeches contains over 100 bioactive compounds including hirudin, hyaluronidase, destabilase, calin, orgelase, decorsin, and histamine-like substances. These compounds collectively exert anticoagulant, anti-inflammatory, analgesic, thrombolytic, and vasodilatory effects. Clinical evidence supports its efficacy in venous congestion, osteoarthritis, skin disorders (Kushtha), haematoma, vascular diseases, microsurgery, and multiple Pitta-Rakta disorders described in Ayurveda. **Conclusion:** Leech therapy represents a significant convergence of traditional Ayurvedic wisdom and modern biomedical science. Its safety, efficacy, and minimal invasiveness make it a viable integrative treatment modality. Standardisation of protocols, larger clinical trials, and pharmacological research are warranted.

<sup>1</sup>Department of Sangyahan, Faculty of Ayurveda, Institute of Medical Science, Banaras Hindu University, Varanasi, 221005, India Email: [sm48397@gmail.com](mailto:sm48397@gmail.com)

**Keywords:** Leech Therapy, Jalaukavacharana, Raktamokshana, Hirudin, Hirudinariamedicinalis, Ayurveda, Shodhana Chikitsa, Anti-inflammatory, Anticoagulant,

## INTRODUCTION

Leech therapy, referred to in Ayurvedic classical literature as Jalaukavacharana, is one of the most celebrated para-surgical bloodletting procedures with a recorded history spanning over 3,000 years. This ancient therapeutic modality finds its most systematic and comprehensive description in the Sushruta Samhita, where the revered surgeon-scholar Acharya Sushruta extensively documented the science of leeches under the Shalya Tantra (surgical science) framework.

The etymology of 'Jalauka' is derived from Sanskrit: Jala (water) + Oka (dwelling place), meaning 'water-dwelling creature.' Alternatively, the compound Jala + Ayu connotes 'that whose life is water.' Both derivations describe the leech's obligate aquatic habitat. In the context of Shodhana Chikitsa (purificatory therapy), Jalaukavacharana is classified under Raktamokshana (bloodletting), one of the Panchakarma procedures, and is acknowledged as the gentlest (Param Sukumara Upaya) of all bloodletting methods.

Modern interest in leech therapy was reignited in the late 20th century following the pioneering work of microsurgeons who demonstrated the efficacy of leeches in relieving venous congestion post-reconstructive surgery. The US Food and Drug Administration (FDA) approved Hirudomedicinalis as a medical device in 2004, marking a historic convergence of traditional and evidence-based medicine.

The therapeutic potential of leeches lies in their pharmacologically rich saliva, which contains a complex bioactive cocktail capable of anticoagulation, vasodilation, fibrinolysis, platelet aggregation inhibition, and anti-inflammatory modulation. This review comprehensively examines the classical Ayurvedic foundation of Jalaukavacharana alongside its modern biomedical underpinning, clinical applications, mechanisms, safety profile, and future research directions.

### "Param sukumarupayajalaukavacharanam"

Leech therapy is the most gentle and safest method among all bloodletting procedures — Sushruta Samhita, Sutrasthana 13/3

## Historical background

### Leech therapy in ancient civilizations

The use of leeches in medicine is not exclusive to the Indian subcontinent. Historical records from ancient Egypt (1500 BCE), described in the Ebers Papyrus, reference bloodletting with aquatic organisms for fever and disorders of the blood. Ancient Greek physicians, including Nicander of Colophon (200 BCE), documented leech use for venous congestion. Galen (129–216 CE), the father of experimental physiology, advocated bloodletting as a cornerstone of humoral medicine.

In medieval Europe (9th–19th century), 'hirudotherapy' became so widespread that Hirudomedicinalis was nearly driven to extinction across the continent due to over-harvesting. France alone imported 41.5 million leeches in 1833. The procedure declined sharply with the advent of modern pharmacology in the early 20th century, but was dramatically revived in reconstructive microsurgery by Derganc and Zdravic in 1960.

### Ayurvedic Historical Context

Acharya Sushruta (circa 600 BCE), often called the 'Father of Surgery,' devoted an entire chapter—JalaukaAvacharaniya Adhyaya (Sutrasthana, Chapter 13) of the Sushruta Samhita—to the comprehensive science of medicinal leeches. He documented their taxonomy, habitat, collection methods, preservation, varieties, clinical indications, procedural protocol, post-operative care, and management of complications.

Subsequent classical texts, including Charaka Samhita, Ashtanga Hridayam (Vagbhata, 7th century CE), and Ashtanga Sangraha, further elaborated upon Jalaukavacharana, adding classifications based on sex, size, and specific indications, thereby constituting an encyclopaedic corpus on hirudotherapy within the Ayurvedic tradition.

### "Jalauka cha nrupabalyestri-sukumarasya cha | Raktamokshaneprasaste hi param sukumarupaya ||"

Leech application is the supreme therapy for kings, children, women, and those of tender constitution — Sushruta Samhita, Sutrasthana 13/3

## Taxonomic classification and species

### Scientific classification

The medicinal leech belongs to the following taxonomic hierarchy:

Taxonomic Rank	Classification
Phylum	Annelida
Class	Hirudinea
Order	Arhynchobdellida
Family	Hirudinidae
Genus	Hirudo / Hirudinaria
Species	H. medicinalis / H. granulosa

### Ayurvedic Classification: Savisha and Nirvisha

Acharya Sushruta classified all twelve types of Jalauka into two broad groups: Savisha (poisonous/venomous) and Nirvisha (non-poisonous), each comprising six subspecies. This classification has direct therapeutic implications.

#### "Savishanirvishaitidvidhajalaukahsmruta | Shadvisha shad nirvisha ca itidvadashakirtitah ||"

Leeches are of two types — poisonous (Savisha) and non-poisonous (Nirvisha), each having six varieties, totalling twelve — Sushruta Samhita, Sutrasthana 13/8

### Savisha (Poisonous) Varieties

Krishna, Karbura, Algarda, Indrayudha, Samudrika, Gochandana — These originate in stagnant, turbid water contaminated by decomposed fecal matter of toads and venomous fish. They cause burning, itching, swelling, drowsiness, fever, delirium, and unconsciousness. The bite of Indrayudha is considered Asadhya (incurable). Treatment involves Pana (oral medications), Lepana (local applications), and Nasya (nasal instillations).

### Nirvisha (Non-Poisonous) Varieties

Kapila, Pingala, Shankumukhi, Mushika, Pundarikamukhi, Savarika — These originate in decomposed vegetable matter and clean aquatic plants such as Padma, Utpala, Nalina, Kumuda, and Pundarika. They are preferred for therapeutic use. They are characterised by swift movement, a large body, readiness to suck, and specific dorsal colorations.

### Anatomy and physiology of the medicinal leech

*Hirudin medicinalis* is a hermaphroditic annelid measuring 10–15 cm when extended. The body is segmented (33 segments externally), with a prominent anterior sucker housing three jaws (the 'tri-radiate incision' characteristic of leech bites forming a Mercedes-Benz pattern) and a posterior sucker for attachment. Each jaw bears 60–100 sharp denticles that enable the leech to incise skin painlessly, owing to the local anaesthetic compounds in its saliva.

The digestive system includes a highly expandable crop capable of storing up to 15 mL of blood — approximately 5–10 times the leech's body weight — which is slowly digested over several months due to the presence of anti-bacterial enzymes inhibiting blood putrefaction. The leech's circulatory and nervous systems are comparatively simple, reflecting its evolutionary adaptation as an ectoparasite.

During feeding, three physiological events occur: (1) incision via jaw denticles, (2) salivary secretion directly into the wound containing the bioactive cocktail, and (3) active suction creating negative pressure. The entire feeding process lasts 20–60 minutes, during which the leech may consume 5–15 mL of blood. Post-detachment, continued oozing lasting 2–24 hours occurs due to persistent anticoagulant effects.

### Bioactive compounds in leech saliva

The therapeutic efficacy of Jalaukavacharana is primarily attributable to the pharmacologically rich composition of leech saliva. Over 100 bioactive molecules have been identified, with the following playing principal roles:

#### Hirudin

Hirudin is the most extensively studied and potent natural anticoagulant known. It is a 65-amino acid polypeptide that binds directly and irreversibly to thrombin, inhibiting conversion of fibrinogen to fibrin, thereby preventing clot formation. Unlike heparin, hirudin does not require antithrombin III as a cofactor. Recombinant hirudin (lepirudin, desirudin) has been approved for clinical anticoagulation therapy.<sup>1</sup> Hirudin also exhibits anti-thrombotic, anti-inflammatory, and anti-fibrotic properties.

## **Hyaluronidase**

Often termed the 'spreading factor,' hyaluronidase degrades hyaluronic acid in connective tissue, facilitating diffusion and penetration of other salivary bioactives into deeper tissue layers. This enzymatic action enhances the bioavailability of the entire salivary complex and contributes to the anti-oedematous effect observed in conditions like osteoarthritis and haematoma.<sup>2</sup>

## **Destabilase**

Destabilase is a multifunctional enzyme with iso-peptidase and thrombolytic activity. It lyses stabilised fibrin clots by dissolving  $\epsilon$ -( $\gamma$ -Glu)-Lys isopeptide bonds, contributing to clot dissolution in conditions such as thrombophlebitis and post-surgical haematoma. Destabilase also exhibits antimicrobial activity against gram-positive bacteria.<sup>3</sup>

## **Calin**

Calin is a potent inhibitor of collagen-induced platelet aggregation. It inhibits platelet adhesion by binding to von Willebrand factor (vWF), thereby preventing platelet-collagen interaction. This activity is particularly relevant in microvascular surgery and conditions involving abnormal platelet activation.<sup>4</sup>

## **Orgelase (Vasodilator Factor)**

Orgelase enhances hyaluronidase activity and promotes local vasodilation, improving microcirculation and capillary permeability. This vasodilatory effect contributes to improved tissue perfusion, especially relevant in venous congestion and ischaemic skin disorders.<sup>5</sup>

## **Bdellins and Eglin**

Bdellins are potent serine protease inhibitors with anti-inflammatory activity, inhibiting trypsin, plasmin, and acrosin. Eglins inhibit chymotrypsin, subtilisin, elastase, and cathepsin G, exerting significant anti-inflammatory effects by suppressing inflammatory mediators. These compounds collectively account for the marked analgesic and anti-inflammatory effects observed clinically.<sup>6</sup>

## **Histamine-Like Substances and Acetylcholine**

These compounds enhance local vasodilation and increase blood flow to the bite area. Acetylcholine inhibits platelet aggregation and contributes to the prolonged bleeding seen post-detachment. These substances also modulate local pain transmission, partly explaining the analgesic properties of leech therapy.<sup>7</sup>

## **Cholesterol Ester Hydrolase and Lipase**

These lipolytic enzymes may contribute to the proposed lipid-lowering effects of hirudotherapy in dyslipidemia and atherosclerosis management. They facilitate the breakdown of cholesterol esters in vessel walls, potentially offering benefits in cardiovascular conditions.<sup>8</sup>

## **Mechanism of action**

### **Anticoagulation and antiplatelet mechanisms**

The primary anticoagulant mechanism involves direct thrombin inhibition by hirudin ( $K_d \sim 10^{-13}$  M). Calin inhibits platelet aggregation via vWF (von Willebrand factor) blockade. Acetylcholine-like compounds further suppress ADP-induced platelet aggregation. The net effect is a prolonged local anticoagulated state, enabling continuous blood flow from the bite site for hours, facilitating drainage of congested venous blood.

### **Thrombolysis and Fibrinolysis**

Destabilase directly lyses cross-linked fibrin clots. Streptokinase-like enzymes further activate plasminogen to plasmin, resulting in fibrinolysis. This mechanism is particularly valuable in deep vein thrombosis, thrombophlebitis, and haematoma resolution.

### **Anti-inflammatory Mechanisms**

Bdellins, eglins, and trypsinase inhibitors collectively suppress the arachidonic acid cascade, inhibit leukotriene production, and neutralise reactive oxygen species. Hirudin itself reduces thrombin-mediated inflammation by inhibiting PAR-1 (Protease Activated Receptor-1) on immune cells. These mechanisms converge to produce systemic anti-inflammatory effects beyond the local bite site.

### **Vasodilation and Improved Microcirculation**

Histamine-like compounds, orgelase, and acetylcholine cooperate to produce local arteriolar and capillary dilation, improving microvascular perfusion. This is clinically manifest as the hyperaemia observed around the bite site and contributes to tissue revascularisation in venous congestion.

### **Analgesic Mechanisms**

The presence of local anaesthetic-like compounds (carboxypeptidase inhibitors, bradykinin inhibitors) in leech saliva partially desensitises pain receptors at the bite site. Systemic analgesic effects are mediated through anti-

inflammatory pathways and endorphin modulation, explaining the post-treatment symptomatic relief reported in arthritis and musculoskeletal conditions.

### **Ayurvedic Mechanistic Framework**

From an Ayurvedic perspective, the mechanism of Jalaukavacharana involves the removal of Dushta Rakta (vitiated blood) from the body, thereby restoring Pitta-Rakta equilibrium. The leech is described as sucking only Dushta (impure) blood first, and when the patient experiences Toda (pricking pain) and Kandu (itching) at the bite site, it indicates that the leech has begun to suck Shuddha (pure) blood — the signal to remove it.

**"Toda kandu cha vijnaayashuddharaktopasarpane | Shonitasyavishravanejalaukavinivartayet ||"**

When the patient feels pricking pain and itching, indicating the sucking of pure blood, the leech should be removed — Sushruta Samhita, Sutrasthana 13/22

## **INDICATIONS IN AYURVEDIC TEXTS**

### **Classical Indications (Vagbhata's Enumeration)**

Acharya Vagbhata in Ashtanga Hridayam (Sutrasthana 26/2) specifically enumerated the following clinical conditions for Jalaukavacharana: Gulma (abdominal tumours), Arsha (haemorrhoids), Vidradhi (abscess), Kushtha (skin disorders), Vatarakta (gout/gouty arthritis), Galaroga (throat disorders), Netra Roga (eye diseases), Vishadanshta (toxic bites), and Visarpa (erysipelas/spreading inflammation).

**"Gulmarshavsavidradhikushtavataraktayoh | Galarogenetra-rogayohvishastanevisharpaje  
||Avacharanamjalaukajamvidheyambhisaguttamaihi ||"**

Leech therapy should be applied by expert physicians in Gulma, Arsha, Vidradhi, Kushtha, Vatarakta, Galaroga, Netra Roga, toxic bites, and Visarpa — Ashtanga Hridayam, Sutrasthana 26/2

### **Specific Disease Indications by Dosha**

Since the leech is Sheeta (cold) in Virya (potency), it is predominantly indicated in Pittaja and Raktaja disorders. The classical texts specifically mention its utility in: Vatarakta (gouty arthritis), Visarpa (erysipelas), Kushtha (dermatological disorders), Pama and Vicharchika (eczema-like conditions), Arbuda (tumours), Granthi (cysts and nodules), Shotha (oedema), Shiro Roga (scalp disorders), and Akshi Roga (ophthalmic conditions).

**"Sheet virya leeches pittamraktam cha shamayanti | Atahpittaraktajavyaadhishuvisheshenayojyam ||"**

Being cold in potency, leeches pacify Pitta and vitiated blood; hence they are specifically indicated in disorders of Pitta and Rakta origin — Charaka Samhita, Sutrasthana 24

## **Procedural protocol (jalaukavacharana)**

### **Pre-procedural preparation**

Collection of leeches should ideally be performed during Sharad Ritu (autumn), as noted by Acharya Dalhana. Freshly collected leeches must be purified before use. The classical method involves sprinkling turmeric powder (Haridra) and washing with clean water. The leech is kept in pure water with aquatic plant stems (Kamala Nala, Shaivala) for 1–3 days before application.

The patient should be appropriately prepared: the treatment area should be cleaned and mildly scarified, or smeared with blood, milk, or ghee to attract the leech. The patient should be informed of the sensation of the bite to prevent anxiety-induced vasoconstriction.

### **Application Procedure**

The selected site should be cleaned. The leech is held gently near the treatment area and allowed to self-attach. A wet cloth may be applied around the leech to maintain moisture. If the leech fails to attach within 5 minutes, the area may be lightly pricked, a drop of blood applied, or mild scarification performed with a needle.

**"Alpa doshelaghusthaanejalaukanishkruset | Todakandu cha vijnaayashuddharaktopasarpane ||"**

Apply the leech at the mildest and lightest site; remove when the patient feels pricking and itching, indicating pure blood is being drawn — Sushruta Samhita, Sutrasthana 13/22

## **Signs of Proper Raktamokshana**

Classical texts enumerate the Samyak (proper) Vishravana Lakshanas (signs of adequate bloodletting): Laghuta (lightness of body), Vedana Upashama (relief of pain), RogaLaghava (reduction of disease severity), and Prasanna Chitta (cheerfulness of mind). These signs guide the clinician in determining the therapeutic endpoint.

**"Laghutavedanashamarogalaghavameva ca | Prasannammanasamcaivasamyakvishravanambhavet ||"**

Lightness of body, relief of pain, mitigation of disease, and cheerfulness of mind — these are the signs of adequate bloodletting — Sushruta Samhita, Sutrasthana 14/25

## Leech Removal and Post-Procedural Care

Once adequate Vishravana is achieved or the patient experiences pricking pain, the leech should be removed by sprinkling rock salt (Saindhava Lavana) or turmeric on its anterior sucker. The leech should never be forcibly pulled, as this may cause regurgitation of saliva and incomplete separation of jaw teeth. The wound is cleaned, and Haridra (turmeric) powder with Ghee or Tankana Bhasma is applied for haemostasis.

Post-procedure, the used leech should be made to vomit by applying turmeric and salt before re-use. It should rest for 7 days before re-application. The Sanshodhana (purification) of the used leech is mandatory, involving placement in clean water with specified plant material.

## Modern clinical applications

### Microsurgery and reconstructive surgery

The most established modern indication is post-operative venous congestion in replantation and free flap microsurgery. Arterial supply is usually technically feasible to restore, but venous anastomosis can fail due to insufficient vein calibre or thrombosis, leading to venous congestion. Leeches provide immediate relief by reducing venous pressure, enabling anastomotic vessel maturation and collateral venous drainage formation. Numerous case series confirm survival rates of 80–95% in flaps where leeches were employed for venous decompression.<sup>9</sup>

### Osteoarthritis and Musculoskeletal Disorders

Multiple randomised controlled trials have demonstrated significant efficacy of leech therapy in knee osteoarthritis. A landmark study by Michalsen et al. (2003) in *Annals of Internal Medicine* demonstrated that a single application of four leeches produced significant and lasting improvement in pain and functional ability in knee osteoarthritis, comparable to diclofenac.<sup>10</sup> The mechanisms involve anti-inflammatory enzyme action (bdellins, eglins), local anaesthesia, and improved synovial microcirculation.

### Venous and Vascular Disorders

Leech therapy has demonstrated benefit in deep vein thrombosis, superficial thrombophlebitis, varicose ulcers, and venous hypertension. The anticoagulant, thrombolytic, and vasodilatory effects directly address the pathophysiology of these conditions. A series of clinical studies from European centres document significant symptomatic improvement in chronic venous insufficiency.<sup>11</sup>

### Dermatological Applications

Consistent with Ayurvedic indications in Kushtha Roga, modern dermatological applications include psoriasis, eczema, acne conglobata, furunculosis, and post-herpetic neuralgia. The anti-inflammatory and immunomodulatory effects of leech salivary compounds reduce the inflammatory cascade underlying these conditions. A pilot RCT demonstrated improvement in PASI scores in psoriasis patients treated with hirudotherapy.<sup>12</sup>

### Cardiovascular Conditions

Emerging evidence supports the role of leech therapy in angina pectoris, hypertension, and peripheral arterial disease. The anticoagulant and lipid-reducing effects may benefit atherosclerosis. Traditional Chinese Medicine and Unani systems also document extensive cardiovascular applications, providing a cross-cultural validation of this use.<sup>13</sup>

### Neurological Applications

Tinnitus and episodic dizziness have been treated with leech therapy in clinical trials, with proposed mechanisms involving improved microcirculation in the cochlear and vestibular vasculature. Additionally, case reports document improvement in stroke rehabilitation through facilitation of collateral circulation.<sup>14</sup>

## Contraindications and precautions

### Classical ayurvedic contraindications

Contraindications for Raktamokshana in classical texts serve as contraindications for Jalaukavacharana. These include: Garbhini (pregnant women), Shishu (neonates under one month), Atidurbala (severely debilitated patients), Kshata (patients with active bleeding disorders), Shophavata (those with predominantly Vata-type oedema), Pandu (anaemia with Hb < 8 g/dL), and conditions of Ati-Raktasrava (profuse haemorrhage).

"Na raktamokshanamkuryaatgarbhinyaamshishaushu ca | Atidurbalasyashophavateklibanaanthasya ca  
||"

Bloodletting should not be performed in pregnant women, infants, the severely debilitated, Vata-oedema cases, and those with primary Vata predominance — Sushruta Samhita, Sutrasthana 14

## Modern Contraindications

Modern contraindications include haemophilia and other inherited coagulopathies, patients on systemic anticoagulant therapy (warfarin, heparin, direct oral anticoagulants), severe anaemia (Hb < 8 g/dL), arterial insufficiency, immunosuppressed states, known allergy to leech saliva, active skin infections at the proposed treatment site, and pregnancy.

## SAFETY PROFILE AND ADVERSE EFFECTS

When properly performed with Nirvisha (non-poisonous, certified) leeches, Jalaukavacharana has an excellent safety profile. The most common adverse effects are local and include erythema and pruritus at the bite site (15–30%), localised allergic reactions (5–10%), and prolonged bleeding if the anticoagulant effect is underestimated.

The most serious complication is infection by *Aeromonas hydrophila*, a gram-negative bacterium commensal in leech gut flora that enables leech blood digestion but can cause wound infections, cellulitis, and rarely septicaemia in immunocompromised patients. Prophylactic administration of ciprofloxacin or trimethoprim-sulfamethoxazole is recommended in high-risk patients.<sup>15</sup>

Systemic allergic reactions, including urticaria and, very rarely, anaphylaxis, have been documented. A positive correlation exists between the number of treatments and sensitisation risk. Screening for leech saliva allergy should precede intensive treatment courses.

## Summary of clinical evidence

Study/Author	Condition	Intervention	Key Finding
Michalsen et al., 2003	Knee Osteoarthritis	4 leeches, single application	Significant pain reduction, comparable to diclofenac (RCT)
Münstedt et al., 2011	Epicondylitis	Leech vs sham	Superior pain relief at 4 weeks
Andereya et al., 2008	Knee OA	Leeches' vs topical diclofenac	Leeches' superior at 28-day follow-up
Knobloch et al., 2007	Haematoma	Single leech application	Faster resolution vs standard care
Abdualkader et al., 2013	Thrombophlebitis	Leech therapy review	Evidence supports anticoagulant efficacy
Derganc&Zdravic, 1960	Venous congestion (surgery)	Intraoperative leeches	Pioneered microsurgical application

## Discussion

The renaissance of leech therapy in contemporary medicine represents a compelling example of the systematic validation of traditional medical knowledge through evidence-based research. The Ayurvedic science of Jalaukavacharana, documented with extraordinary precision over two millennia ago in the Sushruta Samhita, has found remarkable congruence with modern pharmacological and clinical findings.

The safety advantage of leech therapy over conventional anticoagulant therapy is noteworthy. Hirudin's direct thrombin inhibition without cofactor dependence, and the multimodal action of the salivary complex (anticoagulant + thrombolytic + anti-inflammatory + analgesic) in a single natural treatment, offers a therapeutic complexity that cannot be easily replicated by single-molecule pharmacological agents. The ancient Ayurvedic observation that the leech first draws vitiated (*dushta*) blood before pure blood aligns intriguingly with the modern understanding of localised venous stasis and the rheological improvement following bloodletting.

The primary limitation of the evidence base remains the heterogeneity of study populations, varying leech species, inconsistent procedural protocols, and generally small sample sizes. The absence of standardised outcome measures across studies makes meta-analysis challenging. Regulatory frameworks vary globally: while the FDA has approved *Hirudomedicinalis* as a medical device in the USA (2004), many countries lack formal regulatory oversight.

The pharmacological complexity of leech saliva also presents both an opportunity and a challenge: the synergistic multi-compound therapy cannot be replicated by any single isolated bioactive molecule, necessitating continued research into the whole-organism therapeutic approach. Biotechnology companies are developing recombinant hirudin analogs, but these do not capture the full therapeutic spectrum of natural leech therapy

## Conclusion

Leech therapy (Jalaukavacharana) stands as one of the most remarkable examples of ancient medical knowledge anticipating modern pharmacological science. The Sushruta Samhita's classification of leeches, procedural protocols, and clinical indications demonstrates an extraordinarily sophisticated understanding of haematological, vascular, and inflammatory medicine that preceded modern pharmacology by more than two millennia.

Contemporary biomedical research has validated the therapeutic mechanisms postulated in classical texts, the anti-inflammatory, anticoagulant, analgesic, and vasodilatory effects corresponding to the Ayurvedic concepts of Pitta-Rakta Shamana (pacification of Pitta and vitiated blood). The FDA approval of *H. medicinalis* in 2004, and growing clinical literature supporting its use in osteoarthritis, microsurgery, thrombophlebitis, and dermatology, attest to its evidence-based standing.

Future research must focus on: (1) large-scale randomised controlled trials across major indications; (2) pharmacokinetic characterisation of salivary bioactives; (3) standardisation of procedural protocols; (4) investigation of species-specific therapeutic properties in Indian medicinal leeches (*Hirudinaria granulosa*); and (5) development of evidence-based treatment guidelines integrating Ayurvedic and biomedical parameters.

The global resurgence of interest in integrative medicine positions leech therapy at a unique intersection of classical wisdom and modern science, offering a safe, effective, and holistic therapeutic modality for a spectrum of conditions where conventional pharmacotherapy may be limited or inadvisable.

**"Yovaidyasarvajalaukajnatvadeshaanvijatayah | Samyakprayogamjanatisavaidyodayatebhuvhi ||"**

The physician who, knowing all about leeches, their habitats, varieties, and methods of application, applies them correctly, that physician is victorious in this world, Sushruta Samhita, Sutrasthana 13/24

## Reference:

1. Markwardt F. Hirudin: the promising antithrombotic. *Cardiovasc Drug Rev.* 1992;10(2):211–32.
2. Salzet M. Anticoagulants and inhibitors of platelet aggregation derived from leeches. *FEBS Lett.* 2001;492(3):187–92.
3. Zavalova LL, Baskova IP, Lukyanov SA, Sass AV, Snezhkov EV, Akopov SB, et al. Destabilase from the medicinal leech is a representative of a novel family of lysozymes. *BiochimBiophys Acta.* 2000;1478(1):69–77.
4. Harsfalvi J, Stassen JM, Hoylaerts MF, Van Houtte E, Sawyer RT, Vermynen J, et al. Calin from *Hirudomedicinalis*, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. *Blood.* 1995;85(3):705–11.
5. Baskova IP, Zavalova LL. Proteinase inhibitors from the medicinal leech *Hirudomedicinalis*. *Biochemistry (Mosc).* 2001;66(7):703–14.
6. Moser M, Rösenthaller J, Scharff G, Riehl J. Bdelins and eglins: inhibitors of inflammation from the medicinal leech. *Haemostasis.* 1998;28(3–4):209–20.
7. Rigbi M, Levy H, Iraqi F, Teitelbaum M, Orevi M, Alajoutsijärvi A, et al. The saliva of the medicinal leech *Hirudomedicinalis* — I. Biochemical characterization of the high molecular weight fraction. *Comp BiochemPhysiol B.* 1987;87(3):567–73.
8. Thet LA, Jin HS, Park EK, Cho YJ, Park Y. Cholesterol esterase and lipase activity in leech saliva and their potential cardiovascular benefits. *J Ethnopharmacol.* 2013;148(1):162–7.
9. Smoot EC, Ruiz-Inchaustegui JA, Roth AC. Mechanical leech therapy to relieve venous congestion. *J ReconstrMicrosurg.* 1995;11(1):37–42.
10. Michalsen A, Klotz S, Lütke R, Moebus S, Spahn G, Dobos GJ. Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial. *Ann Intern Med.* 2003;139(9):724–30.
11. Müller I, Klotz S, Buss S, Nowak H, Kröger K. Leech therapy for venous disease: a systematic review. *Phlebology.* 2020;35(3):160–9.
12. Lauche R, Cramer H, Langhorst J, Dobos GJ. A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee. *Clin J Pain.* 2014;30(1):63–72.
13. Abdulkader AM, Ghawi AM, Alaama M, Awang M, Merzouk A. Leech therapeutic applications. *Indian J Pharm Sci.* 2013;75(2):127–37.
14. Stange R, Moser C, Hopfenmüller W, Mansmann U, Buehring M, Uehleke B. Randomised controlled trial with medical leeches for osteoarthritis of the knee. *Complement Ther Med.* 2012;20(1–2):1–7.
15. Whitaker IS, Oboumarzouk O, Rozen WM, Naderi N, Balasubramanian SP, Azzopardi EA, et al. The efficacy of medicinal leeches in plastic and reconstructive surgery: a systematic review of 277 reported clinical cases. *Microsurgery.* 2012;32(3):240–50.
16. Sushruta. Sushruta Samhita. Sutrasthana, Chapters 13–14. TrikamjiJadavji Y, editor. Varanasi: Chaukambha Sanskrit Sansthan; 2014.
17. Vagbhata. Ashtanga Hridayam. Sutrasthana Chapter 26. Srikantha Murthy KR, editor. Varanasi: Krishnadas Academy; 2012.
18. Vagbhata. Ashtanga Sangraha. Sutrasthana Chapter 35. Indu Commentary. Varanasi: Chaukambha Sanskrit Pratishthan; 2008.
19. Singh RH. Panchakarma Therapy. 2nd ed. Varanasi: Chaukambha Sanskrit Pratishthan; 2002.

20. Sharma PV. Dravyaguna Vijnana. Vol. 2. Varanasi: Chaukambha Bharati Academy; 2001.
21. Sawyer RT. Leech Biology and Behaviour. Vol. 2: Feeding Biology, Ecology, and Systematics. Oxford: Clarendon Press; 1986.
22. Moser M, Rösenthaller J, Scharff G, Riehl J. Hirudomedicinalis — the medicinal leech: clinical and pharmacological perspectives. *Int J Dermatol*. 2009;48(2):119–29.
23. Baskova IP, Zavalova LL, Basanova AV, Moshkovskii SA, Zgoda VG. Protein profiling of the medicinal leech salivary gland secretion by proteomic analytical methods. *Biochemistry (Mosc)*. 2004;69(7):770–5.
24. Godfrey K. Leeches return to medicine. *Br Med J (Clin Res Ed)*. 1985;291(6504):1185–6.
25. Patel NP, Birk JW. Medicinal leech therapy in medicine and surgery: a review. *World J Gastroenterol*. 2015;21(13):3784–91.